Related Experiment Video
Updated: Jun 13, 2026
The Transition to an Anterior-Based Muscle Sparing Approach Improves Early Postoperative Function but is Associated with a Learning Curve
Published on: September 7, 2022
Effect of prior Salter or Chiari osteotomy on THA with developmental hip dysplasia
Kenji Tokunaga1, Nadim Aslam, Rad Zdero
1Martin Orthopaedic Biomechanics Laboratory, Shuter Wing, Room 5-066, St Michael's Hospital, 30 Bond Street, Toronto, ON M5B-1W8, Canada.
Background:
Controversy exists regarding the outcome of THA after prior pelvic osteotomy.
Questions/Purposes:
We conducted a retrospective chart and radiographic review to obtain outcome measures for perioperative complications, acetabular and femoral component revisions, Harris hip score, and survivorship and compared these outcomes for patients presenting with developmental dysplasia of the hip treated surgically using THA with and without prior pelvic osteotomy.
Patients And Methods:
We performed 103 primary THAs in 87 patients with osteoarthritis secondary to developmental dysplasia of the hip with a minimum 3-year followup. Previous pelvic osteotomy was performed in 52 hips (Salter, 40; Chiari, nine; Salter and Chiari, three), and 51 hips had no previous surgery (control group).
Results:
The pelvic osteotomy group did not have higher rates of femoral or acetabular intraoperative fracture or dislocation compared with the control group. The overall revision rate was 28.8% in the pelvic osteotomy group compared with 19.6% in the control group. The revision rate for aseptic loosening was 23.1% in the pelvic osteotomy group compared with 17.6% in the control group. Harris hip scores (range, 20-87) were not compromised, and overall survivorship rates 8 years postoperatively were not different at any time between the pelvic osteotomy (83.3%) and control (88.4%) groups.
Conclusions:
Prior pelvic osteotomy did not lead to a higher perioperative complication rate, higher revision rate, compromised Harris hip score, or shortened survivorship in eventual THA in developmental dysplasia of the hip.
Level Of Evidence:
Level III, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.
